Cancer Clinical Trial
Official title:
Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen (TAPA)-Pulsed Dendritic Cell (DC) Therapy and Low Dose GM-CSF, as Consolidation Therapy in Patients With Metastatic Solid Malignancies
Verified date | January 2018 |
Source | Kiromic, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effectiveness of Tumor Associated Peptide Antigens (TAPA) pulsed dendritic cell injections as a potential consolidation therapy for patients with metastatic solid malignancies (SM). The investigators hypothesize that treatment of patients with metastatic SM who demonstrate a tumor response, or whose disease remains stable, after conventional first-line systemic therapy AND who lack an available, potentially curative therapeutic intervention and whose tumor cells and/or blood express at least one (1) TAPA of a defined panel of TAPAs will result in TAPA-specific T-cell responses without significant toxicities. The investigators also hypothesize CD4+ and CD8+ T-cell responses generated against specific TAPAs may translate into clinical antitumor activity.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 31, 2019 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Ability to provide informed consent. 2. Patients at least eighteen (18) years of age with histologically proven metastatic solid malignancies (SM) AND whose SM demonstrates a response, or whose disease remains stable, after conventional, first-line systemic therapy, AND who lack any available, potentially curative therapeutic intervention, will be eligible for participation in this study. 3. Expression of one (1) or more of the following TAPAs; Sp17, AKAP-4, Ropporin, PTTG-1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1, by either reverse transcriptase polymerase chain reaction (RT-PCR) and/or immunocytochemistry, Western blotting or ELISA, in neoplastic cells and/or blood. For HER-2/neu expression, positive FISH results are acceptable. All lab tests will be performed in a CLIA certified facility 4. Presence of measurable or evaluable disease. 5. Patients must not have any active infectious process. 6. Patients must have a negative test for HIV, Hepatitis A, B, and C. 7. Patients must not be receiving active immunosuppressive therapy. 8. Patients must have discontinued systemic antineoplastic therapy (including endocrine and biological agents, as well as systemic corticosteroids) at least three (3) to four (4) weeks prior to enrollment. Toxicities from previous therapies must be grade 1 or less. 9. Patients may not have any known allergy to GM-CSF. 10. Patients must be willing to provide at least 250 mls of whole blood obtained by phlebotomy and/or consent to leukapheresis for DC generation. 11. Adequate renal and hepatic function (creatinine = 2.0 mg/dl, bilirubin = 2.0 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) = 4X upper limit of normal range). 12. Adequate hematologic function (Platelets = 60,000/mm3, lymphocytes = 1,000 mm3, neutrophils = 750/mm3, hemoglobin = 10.0 g/dl). 13. Karnofsky performance status = 70%. 14. Expected survival = 6 months. 15. Patient Human Leucocyte Antigen (HLA) typing should demonstrate HLA-A*01, and/or HLA-A*02, and/or HLA-A*24 subtype restriction. 16. Either a female or male of reproductive capacity wishing to participate in this study must be using, or agree to use, one or more types of birth control during the entire study and for 3 months after completing the study. Birth control methods may include condoms, diaphragms, birth control pills, spermicidal gels or foams, anti-gonadotropin injections, intrauterine devices (IUD), surgical sterilization, or subcutaneous implants. Another choice is for a subject's sexual partner to use one of these birth control methods. Women of reproductive capacity will be required to undergo a urine pregnancy test before completion of the post-screening informed consent process. Exclusion Criteria: 1. Patients without confirmed metastatic SM and/or response to conventional, first-line systemic therapy using standard RECIST criteria, or patients with confirmed metastatic SM and/or response to conventional, first-line systemic therapy using standard RECIST criteria, but who have an available, potentially curative therapeutic option will be excluded from participation in this study. 2. Patients without measurable or evaluable disease. 3. Patients receiving cytotoxic therapy (including endocrine and biological agents), radiation therapy, immunotherapy or non-topical steroids, within three (3) weeks of enrollment. 4. Active immunosuppressive therapy (excluding topical steroids) for any other condition. 5. Persistent fever (>24 hours) documented by repeated measurement or active, uncontrolled infection within 4 weeks of enrollment. 6. Active ischemic heart disease or history of myocardial infarction within six months. 7. Active autoimmune disease, including, but not limited to, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Ankylosing Spondylitis (AS), and Rheumatoid Arthritis (RA). 8. Pregnancy or breast feeding. 9. Active second invasive malignancy, other than basal cell carcinoma of the skin. 10. Life expectancy = 6 months. 11. Patients with contraindications to CYP and/or GM-CSF. 12. History of allergy to CYP and/or GM-CSF. 13. Patients who have received organ transplants. 14. Patients with psychological or geographic conditions that prevent adequate follow-up or compliance with the study protocol. 15. Patients diagnosed with central nervous system (CNS) metastases or involvement at any time during disease course are excluded from the study. 16. Patient with HLA alleles not belonging to any of the following subtypes: HLA-A*01, or HLA-A*02, or HLA-A*24. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kiromic, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of adverse events due to administration of TAPA-pulse DC vaccine | every 7 days up to 5 months | ||
Secondary | Immunological efficacy as indicated by T-cell cytokine levels | up to 5 months | ||
Secondary | Immunological efficacy as determined by a positive delayed type hypersensitivity (DTH) skin test | up to 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|